JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, L.
Right arrow Articles by Pardee, A. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, L.
Right arrow Articles by Pardee, A. B.

 Previous Article  |  Next Article 

Journal of Virology, November 1998, p. 8952-8960, Vol. 72, No. 11
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Tat Protein Induces Human Immunodeficiency Virus Type 1 (HIV-1) Coreceptors and Promotes Infection with both Macrophage-Tropic and T-Lymphotropic HIV-1 Strains

Lili Huang,1,2,* Irene Bosch,1,2 Wolfgang Hofmann,3,4 Joseph Sodroski,3,4 and Arthur B. Pardee1,2

Divisions of Cancer Biology1 and Human Retrovirology,3 Dana-Farber Cancer Institute, and Departments of Biological Chemistry and Molecular Pharmacology2 and Pathology,4 Harvard Medical School, Boston, Massachusetts 02115

Received 27 May 1998/Accepted 6 August 1998

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Chemokine receptors CCR5 and CXCR4 are the primary fusion coreceptors utilized for CD4-mediated entry by macrophage (M)- and T-cell line (T)-tropic human immunodeficiency virus type 1 (HIV-1) strains, respectively. Here we demonstrate that HIV-1 Tat protein, a potent viral transactivator shown to be released as a soluble protein by infected cells, differentially induced CXCR4 and CCR5 expression in peripheral blood mononuclear cells. CCR3, a less frequently used coreceptor for certain M-tropic strains, was also induced. CXCR4 was induced on both lymphocytes and monocytes/macrophages, whereas CCR5 and CCR3 were induced on monocytes/macrophages but not on lymphocytes. The pattern of chemokine receptor induction by Tat was distinct from that by phytohemagglutinin. Moreover, Tat-induced CXCR4 and CCR5 expression was dose dependent. Monocytes/macrophages were more susceptible to Tat-mediated induction of CXCR4 and CCR5 than lymphocytes, and CCR5 was more readily induced than CXCR4. The concentrations of Tat effective in inducing CXCR4 and CCR5 expression were within the picomolar range and close to the range of extracellular Tat observed in sera from HIV-1-infected individuals. The induction of CCR5 and CXCR4 expression correlated with Tat-enhanced infectivity of M- and T-tropic viruses, respectively. Taken together, our results define a novel role for Tat in HIV-1 pathogenesis that promotes the infectivity of both M- and T-tropic HIV-1 strains in primary human leukocytes, notably in monocytes/macrophages.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Human immunodeficiency virus type 1 (HIV-1) Tat protein, a potent viral transactivator, is implicated in HIV-1 pathogenesis not only by its indispensability for virus replication (23) but also by its capacity to prime quiescent T cells for productive HIV-1 infection (31) and induce apoptosis in uninfected T cells (30, 56, 61). The mechanism(s) underlying Tat-induced permissivity for productive HIV-1 infection by T-cell line (T)-tropic strains (31) has yet to be revealed. The inefficiency of HIV-1 infection in quiescent T cells may be due to decreased entry of HIV-1, premature termination of reverse transcription, or inefficient integration of HIV-1 provirus into chromosomes (19, 38, 55, 59). Tat could directly or indirectly affect multiple steps in the virus life cycle to facilitate HIV-1 infection, considering its pleiotropic biological properties, such as regulation of both viral and cellular gene expression (7, 23, 32, 51, 57, 60) and modulation of growth of various cell types (26-28, 31, 45), as well as its release from infected cells and its acting on bystander uninfected cells in a paracrine fashion (9, 16, 30, 36, 56, 61, 62).

In an attempt to elucidate the mechanism(s) underlying Tat-enhanced HIV-1 infection, we tested the possibility that Tat facilitates virus entry into target cells by regulating HIV-1 entry receptors. HIV-1 entry requires CD4 as well as other coreceptors, which primarily include chemokine receptors CXCR4 and CCR5 (1, 3, 10, 12, 14, 17). Macrophage (M)-tropic HIV-1 strains, which infect primary macrophages and lymphocytes, mainly utilize CCR5 as a coreceptor (1, 10, 12, 14), while T-tropic HIV-1 strains, which infect lymphocytes and T-cell lines, utilize CXCR4 as a coreceptor (3, 17). Moreover, dualtropic HIV-1 strains, which infect macrophages, lymphocytes, and T-cell lines, utilize both CCR5 and CXCR4 (13). In addition to CCR5 and CXCR4, other chemokine receptors, such as CCR3, CCR2b, and ChemR1, are also utilized by a restricted subset of M-tropic and dualtropic virus strains (10, 13, 49). The importance of the expression levels and patterns of these chemokine receptors for HIV-1 infectivity is underscored by the recent findings from in vivo studies that individuals homozygous for defective CCR5 alleles are resistant to primary M-tropic HIV-1 infection and individuals heterozygous for the mutated CCR5 alleles have slower disease progression than those homozygous for normal CCR5 alleles (11, 22, 33, 39, 41, 50). It has also been shown by in vitro studies that increased cell surface expression of coreceptors correlates with increased infectivity of HIV-1 (1, 3, 8, 10, 12, 14, 17, 25, 44, 47, 58). Therefore, we examined the effect of Tat on chemokine receptor expression and also tested the possibility that Tat promotes HIV-1 entry. We found that Tat differentially induced CXCR4, CCR5, and CCR3 expression in peripheral blood mononuclear cells (PBMCs) and that the induction of CCR5 and CXCR4 expression correlated with Tat-enhanced infectivity of M- and T-tropic viruses, respectively.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Cell cultures. PBMCs were isolated from healthy donors by Ficoll-Paque (Pharmacia, Uppsala, Sweden) density gradient centrifugation and were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 U of penicillin/ml, and 100 µg of streptomycin/ml. In most assays (for immunofluorescence staining or single-round infection), cells were seeded into 6-well plates at a density of 106 per ml and were cultured for the indicated number of days at 37°C in the presence of Tat protein or phytohemagglutinin (PHA; Sigma Chemical, St. Louis, Mo.). Control cells received the same amount of Tat-dissolving buffer. For antibody blocking experiments, prior to addition to PBMC cultures, Tat protein (100 ng/ml) was incubated at room temperature for 1 h with 1 µl of anti-Tat polyclonal rabbit antiserum (National Institutes of Health [NIH] AIDS Reagent Program) or normal rabbit serum, or with 100 µl of anti-Tat monoclonal antibody (MAb) supernatant (MAb clone 15.1; NIH AIDS Reagent Program) or control hybridoma supernatant.

Purification of Tat protein. Recombinant Tat protein was purified to greater than 95% homogeneity as described elsewhere (18), and the protein concentration was determined by amino acid analysis with an Automatic Amino Acid Analyzer (Applied Biosystems). The biological activity of purified Tat was assessed by chloramphenicol acetyltransferase (CAT) assays measuring transactivation of the HIV-1 long terminal repeat (LTR) by Tat in U38 cells stably transfected with the LTR-CAT gene.

Immunofluorescence staining and flow cytometric analysis. Cells were harvested in cold phosphate-buffered saline (PBS) containing 0.1% sodium azide and 1% bovine serum albumin. All subsequent staining procedures were carried out in the above staining buffer at 4°C. For indirect immunofluorescence staining for CXCR4, CCR5, and CCR3, cells were incubated with MAbs to CXCR4 (12G5; NIH AIDS Reagent Program), CCR5 (2D7; Pharmingen, San Diego, Calif.), or CCR3 (7B11; NIH AIDS Reagent Program) for 20 min, washed, and further incubated with a secondary phycoerythrin-labeled anti-mouse immunoglobulin G antibody (Sigma). For double staining of cells for CD14 and CXCR4, CD14 and CCR5, or CD14 and CCR3, cells were incubated with fluorescein isothiocyanate-labeled anti-CD14 MAb (Pharmingen), followed by indirect staining for CXCR4, CCR5, or CCR3. Stained cells were then washed, fixed in 3.7% formaldehyde in PBS, and analyzed on a FACScan flow cytometer (Becton Dickinson, San Jose, Calif.).

Reverse transcriptase PCR (RT-PCR). Two micrograms of total RNA isolated from PBMCs by using TRIzol reagent (Gibco BRL, Grand Island, N.Y.) was primed with oligo(dT) and reverse transcribed into cDNA in a 30-µl reaction mixture containing Moloney murine leukemia virus reverse transcriptase (RT; Gibco BRL). A series of increasing amounts of cDNA, 0.5, 1, and 2 µl, from the cDNA reaction mixture were subjected to PCR amplification by using AmpliTaq DNA polymerase (Perkin-Elmer Cetus, Norwalk, Conn.) in a TRIO-Thermoblock (Biometra) for 30 cycles of denaturing at 94°C for 30 s, annealing at 60°C for 40 s, and extension at 72°C for 1.5 min, followed by a final extension at 72°C for 5 min. The following primers were used: for CXCR4, 5'-GTTACCATGGAGGGGATCAG-3' and 5'-CAGATGAATGTCCACCTCGC-3'; for CCR5, 5'-GGTGGAACAAGATGGATTAT-3' and 5'-CATGTGCACAACTCTGACTG-3'; for CCR3, 5'-TGTGGCTATCCTTCTCTCTTCC-3' and 5'-AGGCAATTTTCTGCATCTGACC-3'; and for beta -actin, 5'-CATCCTCACCCTGAAGTACC-3' and 5'-GGTGAGGATCTTCATGAGGT-3'.

Single-round infection assays. Reporter recombinant HIV-1 viruses with different envelope (Env) proteins were generated by cotransfection of 2 × 106 HeLa cells by the calcium phosphate method with 20 µg of an HIV-1 reporter plasmid and 2 µg of pSVIIIenv, encoding Env proteins from T-tropic (HXBc2) or M-tropic (ADA or YU2) isolates. We used two kinds of HIV-1 reporter plasmids, a CAT reporter plasmid, pHXBDelta BglCAT, and a green fluorescent protein (GFP) reporter plasmid, pHIVec2GFP, each of which contains an HIV-1 provirus with a deletion in the env gene and a replacement of the nef gene with a CAT or GFP gene. For transfections with the GFP reporter plasmid, pCMVPack, encoding the packaging signals, was also added. The transfected HeLa supernatant containing the recombinant viruses was collected and assayed for RT activity. Equal numbers of RT units of the recombinant viruses were used to infect PBMCs which had been preincubated with a series of increasing concentrations of Tat for 4 days and then washed. Cells were lysed at 48 h postinfection for measurement of CAT activity by thin-layer chromotography, or they were fixed with 3.7% formaldehyde in PBS at day 3, 5, 7 or 9 postinfection for visualization of GFP by fluorescence microscopy or FACScan analysis.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Tat protein induces CXCR4, CCR5, and CCR3 expression in PBMCs. The effects of extracellular Tat on chemokine receptor expression in PBMCs isolated from healthy donors were first examined by RT-PCR. Treatment of primary cultures of PBMCs with Tat (100 ng/ml) for 3 days induced high levels of mRNA expression for CXCR4, CCR5, and CCR3, as demonstrated by semiquantitative RT-PCR (Fig. 1). Further quantitative analysis by densitometry revealed approximately fivefold induction of CXCR4 and CCR5 mRNA expression and approximately twofold induction of CCR3 mRNA expression. These results indicate that Tat induced chemokine receptor expression at the mRNA level.


View larger version (61K):
[in this window]
[in a new window]
  		FIG. 1.   Tat induces CXCR4, CCR5, and CCR3 mRNA expression in PBMCs. Total RNA, isolated from PBMCs cultured for 3 days in the presence (+) or absence (-) of Tat (100 ng/ml), was analyzed for the expression of chemokine receptor mRNA by RT-PCR. A series of increasing amounts of cDNA, 0.5 (lanes 1 and 2), 1 (lanes 3 and 4), and 2 (lanes 5 and 6) µl from a total of 30 µl of cDNA synthesized from 2 µg of total RNA were subjected to PCR amplification. RT-PCR of beta -actin mRNA was included and served as a loading control. The amplified PCR products (1,023 bp for CXCR4, 1,115 bp for CCR5, 321 bp for CCR3, and 394 bp for beta -actin) are shown.

To further determine if Tat induces the surface protein expression of these chemokine receptors, we used indirect immunofluorescence and flow cytometric analysis. Consistent with the RT-PCR results, treatment of PBMCs with Tat (100 ng/ml) for up to 4 days led to four- to fivefold induction of CXCR4 (Fig. 2A) and CCR5 protein expression (Fig. 2B), as well as approximately 1.5-fold induction of CCR3 protein expression (Fig. 2C), in PBMCs. Antibody blocking experiments demonstrated that both an anti-Tat polyclonal antibody and an anti-Tat MAb inhibited the Tat-induced up-regulation of CXCR4 (Fig. 2D) and CCR5 (Fig. 2E) expression, indicating that the observed induction of chemokine receptor expression is indeed due to Tat protein. The overall patterns of induction from all donors tested were similar to those represented in Fig. 2, although there was some individual variability in the absolute values. Time course studies showed that the induction of CXCR4 and CCR5 expression by Tat at 100 ng/ml was detected at day 2, further increased at day 4, sustained until day 8, and decreased to initial pretreatment levels by day 12 (data not shown).


View larger version (90K):
[in this window]
[in a new window]
 

View larger version (56K):
[in this window]
[in a new window]
  		FIG. 2.   Tat induces CXCR4, CCR5, and CCR3 surface protein expression in PBMCs. (A through C) Indirect immunofluorescence staining and FACScan analysis of CXCR4 (A), CCR5 (B), and CCR3 (C) expression in PBMCs cultured in the absence (control) or presence of Tat (100 ng/ml) or PHA (1 µg/ml) for 4 days were carried out as described in Materials and Methods. Lymphocytes were gated according to forward and side scatter, and monocytes/macrophages were gated by using CD14 surface labeling. Percentages of positive cells were set based on negative controls (not shown) and are indicated. (D and E) Inhibition of Tat-induced up-regulation of CXCR4 (D) and CCR5 (E) expression in PBMCs by anti-Tat rabbit antiserum and anti-Tat MAb. Tat was incubated with Tat antiserum or MAb before addition to PBMC cultures. Tat pretreated with control (Con.) rabbit serum and Tat pretreated with control hybridoma supernatant were also included as controls for pretreatment with Tat antiserum or MAb. Fold induction of CXCR4 and CCR5 expression in Tat-treated PBMCs was obtained by comparison with expression in untreated cells, which was set to 1. Data are mean values of duplicates. Results shown are representative of three independent experiments.

Tat protein differentially induces CXCR4, CCR5, and CCR3 expression on monocytes/macrophages and lymphocytes. In uninfected PBMCs, CXCR4 and CCR5 are expressed mainly on lymphocytes and monocytes (5, 35, 58). These cell types are major reservoirs for HIV-1 infection, especially monocyte-derived macrophages, which are the primary targets for M-tropic strains isolated at early stages of HIV-1 infection. Therefore, we wanted to determine if Tat differentially induced the chemokine receptors on different leukocyte subsets. Lymphocytes were gated according to their forward and side scatter, and monocytes/macrophages were gated by using CD14 (a marker for monocytes/macrophages) surface labeling. Interestingly, CXCR4 was induced on both lymphocytes and monocytes/macrophages (Fig. 2A), whereas CCR5 (Fig. 2B) and CCR3 (Fig. 2C) were induced on monocytes/macrophages but not on lymphocytes. Furthermore, the induction of CXCR4, CCR5, and CCR3 on monocytes/macrophages was dramatic. After Tat treatment, the proportion of monocytes/macrophages expressing CXCR4 and CCR5 increased from 16.1 to 89.4% and from 19.4 to 81.7%, respectively (Fig. 2A and B). The proportion of monocytes/macrophages expressing CCR3 upon Tat treatment increased from 49.9 to 86.3% (Fig. 2C). The increased surface labeling of CXCR4, CCR5, and CCR3 on monocytes/macrophages was not due to an increased number of monocytes/macrophages in Tat-treated PBMC cultures, since the number of monocytes/macrophages gated in each sample was the same and Tat treatment did not affect the absolute number of monocytes/macrophages in PBMCs (data not shown).

The pattern of chemokine receptor induction by Tat protein is distinct from that by PHA. Activation of PBMCs by certain cytokines and mitogens leads to up-regulation of chemokine receptors, including CXCR4 and CCR5 (5, 34, 53). In order to determine if Tat-induced chemokine receptor expression is similar to other activation-induced expression, we treated PBMCs in parallel with the mitogen PHA and examined chemokine receptor expression. PHA (1 µg/ml) induced CXCR4, CCR5, and CCR3 expression in PBMCs, but to a lower extent than Tat (Fig. 2A through C). The effects of PHA on chemokine receptor expression on lymphocytes were similar to those of Tat in that both PHA and Tat significantly induced CXCR4, but not CCR5 and CCR3, expression on lymphocytes. However, in contrast to Tat, which dramatically induced the expression of CXCR4, CCR5, and CCR3 on monocytes/macrophages, PHA treatment had no significant effects on CXCR4, CCR5, and CCR3 expression on monocytes/macrophages. The expression of CCR5 and CCR3 was induced by PHA on PBMCs but not on lymphocytes or monocytes/macrophages, suggesting that PHA may induce CCR5 and CCR3 expression on other leukocyte subsets. Taken together, these results indicate that Tat differentially induced the expression of the T-tropic coreceptor (CXCR4) and the M-tropic coreceptors (CCR5 and CCR3), probably through a mechanism distinct from that of PHA.

Tat protein-induced CXCR4 and CCR5 expression is dose dependent. We further determined if Tat-induced chemokine receptor expression was dose dependent. Since CXCR4 and CCR5 are the primary coreceptors for T- and M-tropic HIV-1 strains, respectively, and the overall expression pattern of CCR3, a minor coreceptor for certain M-tropic and dualtropic strains, was similar to that of CCR5, we further examined the expression of CXCR4 and CCR5. Freshly isolated PBMCs were treated with a series of increasing concentrations of Tat (1, 10, 50, 100, 500, and 1,000 ng/ml) for 4 days and then were analyzed for CXCR4 and CCR5 expression. Tat exhibited a dose-response effect of induction of CXCR4 and CCR5 expression in PBMCs, reaching plateaus at around 500 ng/ml (Fig. 3). When PBMCs were gated on monocytes/macrophages and lymphocytes, respectively, different patterns of CXCR4 and CCR5 induction appeared. For CXCR4, Tat-induced expression was observed on both monocytes/macrophages and lymphocytes, and the induction on monocytes/macrophages was much more dramatic than that on lymphocytes (Fig. 3A), consistent with the results shown in Fig. 2A. Moreover, on monocytes/macrophages, Tat was able to give rise to approximately 3.5-fold induction at 10 ng/ml and to the highest level of induction (around sevenfold) at 50 ng/ml, whereas on lymphocytes the induction of CXCR4 expression required Tat at higher concentrations (>10 ng/ml) and reached the highest levels (around fourfold) at 500 ng/ml (Fig. 3A). For CCR5, Tat-induced expression was observed on monocytes/macrophages but not on lymphocytes (Fig. 3B), again in agreement with the data shown in Fig. 2B. Induction of CCR5 required lower concentrations of Tat than induction of CXCR4, since Tat at 1 ng/ml caused approximately threefold induction of CCR5 expression on monocytes/macrophages (Fig. 3B), whereas no induction of CXCR4 expression occurred at this concentration (Fig. 3A). Overall, monocytes/macrophages were more susceptible to Tat-mediated induction of CXCR4 and CCR5 expression than lymphocytes, and CCR5 was more readily induced than CXCR4.


View larger version (19K):
[in this window]
[in a new window]
  		FIG. 3.   Tat-induced CXCR4 and CCR5 expression is dose dependent. CXCR4 (A) and CCR5 (B) expression was determined by indirect immunofluorescence staining of PBMCs cultured in the presence of a series of increasing concentrations of Tat for 4 days. Lymphocytes and monocytes/macrophages were gated as described in the Fig. 2 legend. The fold induction of CXCR4 and CCR5 expression in Tat-treated cells was obtained by comparison to expression in untreated cells. Data shown are representative of three independent experiments.

Tat protein-induced CXCR4 and CCR5 expression correlates with Tat-enhanced HIV-1 infectivity. Increased cell surface expression of coreceptors correlates with increased infectivity of HIV-1 (1, 3, 8, 10, 12, 14, 17, 25, 44, 47, 58). Thus, significant induction of CXCR4 and CCR5 expression by Tat suggests that Tat is able to promote the infectivity of both T- and M-tropic HIV-1 strains. To confirm this, we used a single-round infection assay to evaluate the entry and early-phase infectivity of HIV-1 viruses containing different Env proteins (10, 20). In the assay, recombinant HIV-1 viruses were generated by cotransfection of HeLa cells with a CAT reporter HIV-1 vector containing an HIV-1 provirus with a deletion in the env gene and a replacement of the nef gene with the CAT gene, as well as with a plasmid expressing Env protein derived from a laboratory-adapted T-tropic isolate (HXBc2) or an M-tropic primary HIV-1 isolate (ADA or YU2). The recombinant viruses were then used at equal numbers of RT units to infect PBMCs which had been cultured with a series of increasing concentrations of Tat (0, 10, 50, 100, 500, and 1,000 ng/ml) for 4 days. At 48 h postinfection, CAT activity in whole-cell lysates was measured to assess the efficiency of the single-round infection. In PBMCs infected with the CAT reporter HIV-1 recombinant viruses containing the T-tropic HXBc2 Env proteins, CAT activity increased in a dose-dependent manner (Fig. 4A and 5A). Treatment with Tat at lower concentrations (<100 ng/ml) resulted in a significant increase in CAT activity. Such an increase was unlikely due to a direct transactivation of HIV-1 LTR by Tat, since direct transactivation of HIV-1 LTR required much higher concentrations (>= 500 ng/ml) of extracellular Tat (references 16 and 31 and data not shown). At 500 ng/ml or higher, Tat could directly transactivate HIV-1 LTR, thus probably contributing to the higher CAT activity observed. Overall, Tat-induced expression of the T-tropic coreceptor CXCR4 correlated with Tat-enhanced infectivity of the T-tropic HIV-1 strain (Fig. 5A). Similar results were obtained when the CAT reporter HIV-1 recombinant viruses containing the M-tropic (ADA or YU2) Env proteins were used (Fig. 4B and C and 5B). The single-round infection assays with Env proteins from either of the two M-tropic strains gave very similar results. In both assays, a roughly twofold increase in CAT activity was achieved at 10 ng of Tat/ml, and a plateau was reached at 100 ng of Tat/ml. The expression of CCR5 was fully induced at 10 ng of Tat/ml, but the CAT activity, reflecting early-phase infectivity, reached a maximum at 100 ng of Tat/ml (Fig. 5B), suggesting that Tat also increased HIV-1 infectivity by other mechanisms besides the induction of chemokine receptors.


View larger version (77K):
[in this window]
[in a new window]
  		FIG. 4.   Tat promotes the infectivity of CAT reporter HIV-1 recombinant viruses. PBMCs were cultured in the presence of increasing concentrations of Tat for 4 days, infected with equal numbers of RT units of CAT reporter recombinant viruses containing HXBc2 (A), ADA (B), or YU2 (C) Env proteins, and analyzed for CAT activity at 48 h postinfection. The experiments were repeated three times, and comparable results were obtained.


View larger version (37K):
[in this window]
[in a new window]
  		FIG. 5.   Tat-induced CXCR4 and CCR5 expression correlates with Tat-enhanced infectivity of both CAT and GFP reporter HIV-1 recombinant viruses. CXCR4 (A) and CCR5 (B) expression was analyzed by indirect immunofluorescence staining of PBMCs cultured in the presence of a series of increasing concentrations of Tat protein for 4 days. The fold increase in the percentage of CXCR4- or CCR5-positive cells in Tat-treated PBMCs was obtained by comparison to untreated cells. The CAT assay results with CAT reporter HIV-1 viruses containing either the T-tropic (HXBc2) (A) or the M-tropic (ADA or YU2) (B) Env proteins were obtained from the autoradiograms shown in Fig. 4, which were scanned with a densitometer. The CAT activity was expressed as the percent chloramphenicol conversion. The fold increase in CAT activity in Tat-treated PBMCs was calculated by comparison to untreated cells. The GFP results were obtained by infecting PBMCs with GFP reporter HIV-1 viruses containing either HXBc2 (A) or YU2 (B) Env proteins for 9 days and analyzing the GFP fluorescence of intact cells with a flow cytometer. The fold increase in the percentage of GFP-positive cells among Tat-treated PBMCs was calculated by comparison to untreated cells.

We further carried out single-round infection assays with GFP reporter recombinant HIV-1 viruses in order to directly examine the proportion of infected cells affected by Tat. Starting from day 3 after infection with GFP reporter viruses containing either the T-tropic (HXBc2) or the M-tropic (YU2) Env proteins, we detected a significant increase in the proportion of GFP-positive cells among Tat-treated PBMCs compared to untreated cells, by visualization of GFP with a fluorescence microscope or by FACScan analysis. The Tat-mediated increase in the percentage of fluorescent cells was time dependent and reached a maximum between 7 and 9 days, with a mean fluorescence value distributing between 103 to 104 U (data not shown). With different cell types, the time required to reach a peak of GFP fluorescence varied. The representative data illustrating the maximum fold increase in the percentage of GFP-positive cells are shown in Fig. 5. Overall, the Tat-mediated increase in the percentage of GFP-positive cells correlated with Tat-enhanced levels of CAT activity and chemokine receptor (CXCR4 or CCR5) expression. Interestingly, PHA (1 µg/ml) was not as potent as Tat in promoting the infectivity of both CAT and GFP reporter HIV-1 recombinant viruses containing the M-tropic Env proteins, but it was quite potent in facilitating the infectivity of recombinant HIV-1 viruses containing the T-tropic Env proteins (data not shown), which correlated with its differential effects on CCR5 and CXCR4 expression in monocytes/macrophages and lymphocytes.

Tat promotes both M- and T-tropic HIV-1 infection in monocytes/macrophages. Tat-mediated enhancement of HIV-1 infection in PBMCs and the dramatic induction by Tat of CXCR4, CCR5, and CCR3 expression on monocytes/macrophages implicate Tat in the promotion of HIV-1 infection in monocytes/macrophages. As demonstrated by single-round infection assays using GFP reporter HIV-1 recombinant viruses, Tat greatly facilitated the infectivity of both M-tropic (Fig. 6A through D) and T-tropic (Fig. 6E through H) viruses in adherent monocytes/macrophages. Subsequent FACScan analysis of the monocytes/macrophages showed that Tat induced a four- to fivefold increase in the percentage of GFP-positive cells (Fig. 7). These results indicate an important role of Tat in HIV-1 infection in monocytes/macrophages.


View larger version (94K):
[in this window]
[in a new window]
  		FIG. 6.   Tat promoted the infectivity of the GFP reporter HIV-1 recombinant viruses in monocytes/macrophages. PBMCs were cultured in the absence (A, B, E, and F) or presence (C, D, G, and H) of Tat (100 ng/ml) for 4 days and were infected with GFP reporter HIV-1 viruses containing the M-tropic (YU2) (A through D) or T-tropic (HXBc2) (E through H) Env proteins for 9 days. After removal of the medium, the adherent cells, largely containing monocytes and monocyte-derived macrophages, were washed off nonadherent cells, fixed, and visualized by fluorescence microscopy to detect GFP fluorescence. Shown here are representative pictures depicting phase-contrast (A, C, E, and G) and fluorescence (B, D, F, and H) imaging. Results obtained from cells infected for 5 to 7 days were comparable to these.


View larger version (36K):
[in this window]
[in a new window]
  		FIG. 7.   The same adherent monocytes/macrophages infected with GFP reporter HIV-1 recombinant viruses shown in Fig. 6 were subsequently analyzed for GFP fluorescence by FACScan analysis. The fold increase in GFP-positive cells after treatment with Tat was obtained by comparison to untreated cells.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

In this study, we demonstrated that extracellular Tat protein differentially induced the expression of chemokine receptors CXCR4, CCR5, and CCR3 in primary cultures of PBMCs. CXCR4, a C-X-C chemokine receptor, was induced on both lymphocytes and monocytes/macrophages, whereas CCR5 and CCR3, the C-C chemokine receptors, were induced on monocytes/macrophages but not on lymphocytes. Moreover, monocytes/macrophages were more susceptible to Tat-mediated induction of CXCR4 and CCR5 expression than lymphocytes, and CCR5 was more readily induced than CXCR4. The great susceptibility of monocytes/macrophages to Tat-mediated induction of chemokine receptors and the selective induction of the M-tropic HIV-1 coreceptors CCR5 and CCR3 on monocytes/macrophages are of particular interest, since monocytes/macrophages are the major target for HIV-1 infection in vivo, especially at early stages of virus infection, and are a primary reservoir for persistent infection (43).

The induction of CXCR4 and CCR5 expression by Tat was dose dependent. The extracellular Tat used here induced high levels of CXCR4 and CCR5 expression at concentrations well below those required for a direct transactivation as determined by us (unpublished data) and others (16, 31), suggesting that Tat mediates CXCR4 and CCR5 expression via an indirect pathway. Two different pathways have been described to mediate cellular and viral effects of extracellular Tat (16, 31, 63). One is through signal transduction and requires lower Tat concentrations; the other is through the direct transactivating effect of Tat and requires higher Tat concentrations. For the signaling pathway, integrin receptors are implicated in mediating extracellular Tat-induced effects (2, 6, 16, 31), and Tat can stimulate mitogen-activated protein kinases and phosphatidylinositol-specific phospholipase C in PBMCs and Jurkat T-cell lines (31, 63). Whether Tat regulates CXCR4 and CCR5 expression through intracellular signaling needs further investigation.

Tat protein can modulate the expression of various cytokines, including tumor necrosis factor alpha (TNF-alpha ), TNF-beta , interleukin 1 (IL-1), IL-2, and IL-6 (7, 28, 51, 57). Recently, several cytokines have been shown to regulate chemokine receptor expression. For instance, IL-2 up-regulates CXCR4, CCR5, and other C-C chemokine receptors in T lymphocytes (5, 34, 40), as well as CCR2 in monocytes (52), and IL-10 induces CCR5, but not CXCR4, in monocytes (53). Therefore, it is possible that Tat induces the expression of cytokines, which in turn stimulate chemokine receptor expression.

The pattern of chemokine receptor induction by Tat was distinct from that by PHA. PHA stimulation induced the expression of CXCR4, but not CCR5 and CCR3, on lymphocytes, which is similar to the effect of Tat on lymphocytes and is also consistent with results obtained by others (5). However, in contrast to Tat, which dramatically induced CXCR4, CCR5, and CCR3 expression on monocytes/macrophages, PHA, an activator of monocytes/macrophages (4), had no significant effect on chemokine receptor expression on this cell type. These results suggest that Tat probably induces chemokine receptor expression via a mechanism distinct from that of PHA.

To our best knowledge, Tat is the first virus-encoded protein shown to induce the expression of HIV-1 coreceptors. Other viral proteins, such as envelope glycoprotein gp120, Nef, and Vpu, have been shown to down-regulate CD4 expression in primary monocytes/macrophages and lymphocytes (24, 29, 37). Tat, in contrast, did not have significant effects on CD4 expression in monocytes/macrophages and lymphocytes (unpublished data). Recent studies demonstrate that the CD4 and CCR5 cell surface concentrations required for efficient infection of M-tropic HIV-1 are interdependent and that the requirement for one is increased when the other is present in a limiting amount (47). In monocytes/macrophages, CD4 expression is low (21, 42), and it is further down-regulated in HIV-1-infected individuals (48). Under those circumstances, changes in coreceptor expression could readily affect the susceptibility of macrophages to HIV-1 infection. Therefore, Tat-mediated induction of coreceptors CXCR4, CCR5, and CCR3 in PBMCs, especially in monocytes/macrophages, could greatly enhance the susceptibility of these cells to HIV-1 infection. This is confirmed by our single-round infection assays using both CAT and GFP reporter HIV-1 recombinant viruses pseudotyped with T- or M-tropic Env proteins. Our results showed that Tat enhanced the early-phase infectivity of T- and M-tropic HIV-1 strains in PBMCs and that such enhancement in T- and M-tropic HIV-1 infectivity correlated with Tat-mediated induction of the expression of CXCR4 and CCR5, respectively. Notably, Tat greatly enhanced the susceptibility of monocyte-derived macrophages to infection by both M- and T-tropic HIV-1 strains. In our system, the T-tropic HIV-1 virus, which is thought to be unable to infect primary monocytes/macrophages, can infect these cells, in agreement with results from others (54). Overall, our results suggest that Tat facilitates HIV-1 infection by inducing coreceptors and thus promoting virus entry.

Besides the induction of chemokine receptors, other mechanisms for the Tat-mediated increase in HIV-1 infectivity were also implied by our data. Tat may modulate other cellular activities and therefore facilitate postentry events of HIV-1 infection. In this regard, Tat has been shown to modulate cytokine expression (7, 51, 57) and increase the activation states of T cells and monocytes (26-28, 31, 45).

Our findings are relevant to in vivo infection in that the concentrations of Tat effective in inducing chemokine receptor expression in our experiments are within the picomolar range and close to the range of extracellular Tat observed in sera from HIV-1-infected individuals (56). In fact, Tat is likely to reach even higher levels in lymphoid tissues of HIV-1-infected individuals due to active viral replication (15, 46, 56). Whether these chemokine receptors are up-regulated in HIV-1-infected individuals has not been well documented. The in vivo situation would be expected to be more complicated than the in vitro situation, in that chemokine receptor expression is regulated by multiple factors, including negative and positive regulators.

In summary, Tat protein induced the expression of HIV-1 primary coreceptors CXCR4 and CCR5 in PBMCs. Such induction in CXCR4 and CCR5 expression correlated with Tat-enhanced infectivity of M- and T-tropic HIV-1 strains, respectively. Moreover, Tat-mediated increases in the infectivity of both M- and T-tropic strains in monocytes/macrophages are prominent and of pathological significance, since macrophages are major reservoirs for HIV-1 infection and primary transmission sites to T cells (43). Our results define a novel role for Tat in HIV-1 pathogenesis. By up-regulating HIV-1 coreceptors and increasing the activation states of T cells and monocytes (26-28, 31, 45), as well as stimulating viral replication (23), Tat greatly promotes HIV-1 infection. This, together with Tat-induced apoptosis in uninfected T lymphocytes (30, 56, 61), contributes to CD4+ T-cell loss in AIDS patients. Thus, our findings should contribute to our understanding of the molecular mechanisms of HIV-1 infection and to better design of prophylactic and therapeutic strategies. Anti-Tat agents and vaccines might potentially be effective in interfering with HIV-1 infection.

    ACKNOWLEDGMENTS

We thank Hyeryun Choe for kindly providing the Env protein-expressing plasmids; the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, for Tat antiserum (contributed by B. Cullen), anti-Tat MAb (contributed by K. Krohn and V. Ovod), anti-CXCR4 MAb 12G5 (contributed by J. Hoxie), and anti-CCR3 MAb 7B11 (contributed by LeukoSite, Inc.); Isaac Rondon and Heather Melichar for help in the transfection/infection protocols; the Dana-Farber flow cytometry lab for performing FACScan analysis; Heide Ford, Debajit Biswas, and Belinda Hall for critical reading and helpful comments on the manuscript; and Chiang Li for helpful discussions.

This work was supported by an NIH National Research Service Award fellowship (2-T32-CA09361) to L.H.

    FOOTNOTES

* Corresponding author. Mailing address: Division of Cancer Biology, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115. Phone: (617) 632-4688. Fax: (617) 632-4680. E-mail: lhuang{at}mbcrr.harvard.edu.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

1. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy, and E. A. Berger. 1996. CC CKR5: a RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-1958[Abstract].
2. Barillari, G., R. Gendelman, R. C. Gallo, and B. Ensoli. 1993. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc. Natl. Acad. Sci. USA 90:7941-7945[Abstract/Free Full Text].
3. Berson, J. F., D. Long, B. J. Doranz, J. Rucker, F. R. Jirik, and R. W. Doms. 1996. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J. Virol. 70:6288-6295[Abstract].
4. Bhardwaj, R., E. Becher, K. Mahnke, M. Hartmeyer, T. Schwarz, T. Scholzen, and T. A. Luger. 1997. Evidence for the differential expression of the functional alpha-melanocyte-stimulating hormone receptor MC-1 on human monocytes. J. Immunol. 158:3378-3384[Abstract].
5. Bleul, C. C., L. Wu, J. A. Hoxie, T. A. Springer, and C. R. Mackay. 1997. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA 94:1925-1930[Abstract/Free Full Text].
6. Brake, D. A., C. Debouck, and G. Biesecker. 1990. Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat. J. Cell Biol. 111:1275-1281[Abstract/Free Full Text].
7. Buonaguro, L., G. Barillari, H. K. Chang, C. A. Bohan, V. Kao, R. Morgan, R. C. Gallo, and B. Ensoli. 1992. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J. Virol. 66:7159-7167[Abstract/Free Full Text].
8. Carroll, R. G., J. L. Riley, B. L. Levine, Y. Feng, S. Kaushal, D. W. Ritchey, W. Bernstein, O. S. Weislow, C. R. Brown, E. A. Berger, C. H. June, and D. C. St. Louis. 1997. Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science 276:273-276[Abstract/Free Full Text].
9. Chang, H. C., F. Samaniego, B. C. Nair, L. Buonaguro, and B. Ensoli. 1997. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 11:1421-1431[Medline].
10. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard, and J. Sodroski. 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148[Medline].
11. Dean, M., M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith, R. Allikmets, J. J. Goedert, S. P. Buchbinder, E. Vittinghoff, E. Gomperts, S. Donfield, D. Vlahov, R. Kaslow, A. Saah, C. Rinaldo, R. Detels, and S. J. O'Brien. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856-1862[Abstract/Free Full Text].
12. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, M. P. Di, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, and N. R. Landau. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666[Medline].
13. Doranz, B. J., J. Rucker, Y. Yi, R. J. Smyth, M. Samson, S. C. Peiper, M. Parmentier, R. G. Collman, and R. W. Doms. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149-1158[Medline].
14. Dragic, T., V. Litwin, G. P. Allaway, S. R. Martin, Y. Huang, K. A. Nagashima, C. Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore, and W. A. Paxton. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673[Medline].
15. Embretson, J., M. Zupancic, J. L. Ribas, A. Burke, P. Racz, R. K. Tenner, and A. T. Haase. 1993. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362:359-362[Medline].
16. Ensoli, B., L. Buonaguro, G. Barillari, V. Fiorelli, R. Gendelman, R. A. Morgan, P. Wingfield, and R. C. Gallo. 1993. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67:277-287[Abstract/Free Full Text].
17. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877[Abstract].
18. Gentz, R., C. H. Chen, and C. A. Rosen. 1989. Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: trans-activation requires mRNA synthesis. Proc. Natl. Acad. Sci. USA 86:821-824[Abstract/Free Full Text].
19. Gowda, S. D., B. S. Stein, N. Mohagheghpour, C. J. Benike, and E. G. Engleman. 1989. Evidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes. J. Immunol. 142:773-780[Abstract].
20. Helseth, E., M. Kowalski, D. Gabuzda, U. Olshevsky, W. Haseltine, and J. Sodroski. 1990. Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J. Virol. 64:2416-2420[Abstract/Free Full Text].
21. Herbein, G., A. G. Doyle, L. J. Montaner, and S. Gordon. 1995. Lipopolysaccharide (LPS) down-regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor (TNF) and IL-1 beta. Clin. Exp. Immunol. 102:430-437[Medline].
22. Huang, Y., W. A. Paxton, S. M. Wolinsky, A. U. Neumann, L. Zhang, T. He, S. Kang, D. Ceradini, Z. Jin, K. Yazdanbakhsh, K. Kunstman, D. Erickson, E. Dragon, N. R. Landau, J. Phair, D. D. Ho, and R. A. Koup. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2:1240-1243[Medline].
23. Jones, K. A. 1993. Tat and the HIV-1 promoter. Curr. Opin. Cell Biol. 5:461-468[Medline].
24. Karsten, V., S. Gordon, A. Kirn, and G. Herbein. 1996. HIV-1 envelope glycoprotein gp120 down-regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor-alpha. Immunology 88:55-60[Medline].
25. Kitchen, S. G., and J. A. Zack. 1997. CXCR4 expression during lymphopoiesis: implications for human immunodeficiency virus type 1 infection of the thymus. J. Virol. 71:6928-6934[Abstract].
26. Lafrenie, R. M., L. M. Wahl, J. S. Epstein, I. K. Hewlett, K. M. Yamada, and S. Dhawan. 1996. HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis. J. Immunol. 156:1638-1645[Abstract].
27. Lafrenie, R. M., L. M. Wahl, J. S. Epstein, I. K. Hewlett, K. M. Yamada, and S. Dhawan. 1996. HIV-1-Tat protein promotes chemotaxis and invasive behavior by monocytes. J. Immunol. 157:974-977[Abstract].
28. Lafrenie, R. M., L. M. Wahl, J. S. Epstein, K. M. Yamada, and S. Dhawan. 1997. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J. Immunol. 159:4077-4083[Abstract].
29. Lenburg, M. E., and N. R. Landau. 1993. Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4. J. Virol. 67:7238-7245[Abstract/Free Full Text].
30. Li, C. J., D. J. Friedman, C. Wang, V. Metelev, and A. B. Pardee. 1995. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 268:429-431[Abstract/Free Full Text].
31. Li, C. J., Y. Ueda, B. Shi, L. Borodyansky, L. Huang, Y. Z. Li, and A. B. Pardee. 1997. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc. Natl. Acad. Sci. USA 94:8116-8120[Abstract/Free Full Text].
32. Li, C. J., C. Wang, D. J. Friedman, and A. B. Pardee. 1995. Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 92:5461-5464[Abstract/Free Full Text].
33. Liu, R., W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. Stuhlmann, R. A. Koup, and N. R. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377[Medline].
34. Loetscher, P., M. Seitz, M. Baggiolini, and B. Moser. 1996. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J. Exp. Med. 184:569-577[Abstract/Free Full Text].
35. Loetscher, P., M. Uguccioni, L. Bordoli, M. Baggiolini, and B. Moser. 1998. CCR5 is characteristic of Th1 lymphocytes. Nature 391:344-345[Medline].
36. Mann, D. A., and A. D. Frankel. 1991. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J. 10:1733-1739[Medline].
37. Mariani, R., and J. Skowronski. 1993. CD4 down-regulation by nef alleles isolated from human immunodeficiency virus type 1-infected individuals. Proc. Natl. Acad. Sci. USA 90:5549-5553[Abstract/Free Full Text].
38. McCune, J. M. 1995. Viral latency in HIV disease. Cell 82:183-188[Medline].
39. Michael, N. L., L. G. Louie, A. L. Rohrbaugh, K. A. Schultz, D. E. Dayhoff, C. E. Wang, and H. W. Sheppard. 1997. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat. Med. 3:1160-1162[Medline].
40. Moore, J. P., and R. A. Koup. 1996. Chemoattractants attract HIV researchers. J. Exp. Med. 184:311-313[Free Full Text].
41. Moore, J. P., A. Trkola, and T. Dragic. 1997. Co-receptors for HIV-1 entry. Curr. Opin. Immunol. 9:551-562[Medline].
42. Moscicki, R. A., E. P. Amento, S. M. Krane, J. T. Kurnick, and R. B. Colvin. 1983. Modulation of surface antigens of a human monocyte cell line, U937, during incubation with T lymphocyte-conditioned medium: detection of T4 antigen and its presence on normal blood monocytes. J. Immunol. 131:743-748[Abstract].
43. Mosier, D., and H. Sieburg. 1994. Macrophage-tropic HIV: critical for AIDS pathogenesis? Immunol. Today 15:332-339[Medline].
44. Naif, H. M., S. Li, M. Alali, A. Sloane, L. Wu, M. Kelly, G. Lynch, A. Lloyd, and A. L. Cunningham. 1998. CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection. J. Virol. 72:830-836[Abstract/Free Full Text].
45. Ott, M., S. Emiliani, L. C. Van, G. Herbein, J. Lovett, N. Chirmule, T. McCloskey, S. Pahwa, and E. Verdin. 1997. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 275:1481-1485[Abstract/Free Full Text].
46. Pantaleo, G., C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-358[Medline].
47. Platt, E. J., K. Wehrly, S. E. Kuhmann, B. Chesebro, and D. Kabat. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864[Abstract/Free Full Text].
48. Rieber, P., and G. Riethmuller. 1986. Loss of circulating T4+ monocytes in patients infected with HTLV-III. Lancet i:270.
49. Rucker, J., A. L. Edinger, M. Sharron, M. Samson, B. Lee, J. F. Berson, Y. Yi, B. Margulies, R. G. Collman, B. J. Doranz, M. Parmentier, and R. W. Doms. 1997. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J. Virol. 71:8999-9007[Abstract].
50. Samson, M., F. Libert, B. J. Doranz, J. Rucker, C. Liesnard, C. M. Farber, S. Saragosti, C. Lapoumeroulie, J. Cognaux, C. Forceille, G. Muyldermans, C. Verhofstede, G. Burtonboy, M. Georges, T. Imai, S. Rana, Y. Yi, R. J. Smyth, R. G. Collman, R. W. Doms, G. Vassart, and M. Parmentier. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725[Medline].
51. Scala, G., M. R. Ruocco, C. Ambrosino, M. Mallardo, V. Giordano, F. Baldassarre, E. Dragonetti, I. Quinto, and S. Venuta. 1994. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J. Exp. Med. 179:961-971[Abstract/Free Full Text].
52. Sica, A., A. Saccani, A. Borsatti, C. A. Power, T. N. Wells, W. Luini, N. Polentarutti, S. Sozzani, and A. Mantovani. 1997. Bacterial lipopolysaccharide rapidly inhibits expression of C-C chemokine receptors in human monocytes. J. Exp. Med. 185:969-974[Abstract/Free Full Text].
53. Sozzani, S., S. Ghezzi, G. Iannolo, W. Luini, A. Borsatti, N. Polentarutti, A. Sica, M. Locati, C. Mackay, T. Wells, P. Biswas, E. Vicenzi, G. Poli, and A. Mantovani. 1998. Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J. Exp. Med. 187:439-444[Abstract/Free Full Text].
54. Stent, G., G. B. Joo, P. Kierulf, and B. Asjo. 1997. Macrophage tropism: fact or fiction? J. Leukoc. Biol. 62:4-11[Abstract].
55. Stevenson, M., T. L. Stanwick, M. P. Dempsey, and C. A. Lamonica. 1990. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9:1551-1560[Medline].
56. Westendorp, M. O., R. Frank, C. Ochsenbauer, K. Stricker, J. Dhein, H. Walczak, K. M. Debatin, and P. H. Krammer. 1995. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375:497-500[Medline].
57. Westendorp, M. O., W. M. Li, R. W. Frank, and P. H. Krammer. 1994. Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J. Virol. 68:4177-4185[Abstract/Free Full Text].
58. Wu, L., W. A. Paxton, N. Kassam, N. Ruffing, J. B. Rottman, N. Sullivan, H. Choe, J. Sodroski, W. Newman, R. A. Koup, and C. R. Mackay. 1997. CCR5 levels and expression pattern correlate with infectibility by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 185:1681-1691[Abstract/Free Full Text].
59. Zack, J. A., S. J. Arrigo, S. R. Weitsman, A. S. Go, A. Haislip, and I. S. Chen. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213-222[Medline].
60. Zauli, G., D. Gibellini, A. Caputo, A. Bassini, M. Negrini, M. Monne, M. Mazzoni, and S. Capitani. 1995. The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. Blood 86:3823-3834[Abstract/Free Full Text].
61. Zauli, G., D. Gibellini, C. Celeghini, C. Mischiati, A. Bassini, P. M. La, and S. Capitani. 1996. Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4+ T lymphocytes. J. Immunol. 157:2216-2224[Abstract].
62. Zauli, G., P. M. La, M. Vignoli, M. C. Re, D. Gibellini, G. Furlini, D. Milani, M. Marchisio, M. Mazzoni, and S. Capitani. 1995. An autocrine loop of HIV type-1 Tat protein responsible for the improved survival/proliferation capacity of permanently Tat-transfected cells and required for optimal HIV-1 LTR transactivating activity. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10:306-316[Medline].
63. Zauli, G., M. Previati, E. Caramelli, A. Bassini, E. Falcieri, D. Gibellini, L. Bertolaso, D. Bosco, I. Robuffo, and S. Capitani. 1995. Exogenous human immunodeficiency virus type-1 Tat protein selectively stimulates a phosphatidylinositol-specific phospholipase C nuclear pathway in the Jurkat T cell line. Eur. J. Immunol. 25:2695-2700[Medline].

Journal of Virology, November 1998, p. 8952-8960, Vol. 72, No. 11
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow